So far, we have proved that IGF2BP3 maintains the stability of EGFR mRNA levels by combining with METTL14 in an m6A-dependent manner and causes drug resistance of CRC cells to cetuximab. This evidence concerns the gene IGF2BP3 and colorectal carcinoma.